|
This is a randomized phase III trial comparing cisplatin with or without gemcitabine in patients with carcinoma of unknown primary and a predicted favorable prognosis. The purpose of this trial is to compare the overall survival rates of patients with carcinoma of unknown primary (CUP) and a predicted favorable prognosis according to the French classification treated with cisplatin with or without gemcitabine.
U.S. FDA Resources
Further study details as provided by Institut Gustave Roussy: Eligibility
Criteria Inclusion Criteria:
Exclusion Criteria:
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT00126269 Contacts
Locations
Sponsors and Collaborators
Investigators
More Information
Keywords provided by Institut Gustave Roussy:
Study placed in the following topic categories:
Additional relevant MeSH terms:
Source: National Library of Medicine (NLM) July 03, 2008 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Browse
|
||

